Optimal model establishment of whole-process management data for CAR-T therapy in China—how should this be done?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Optimal model establishment of whole-process management data for CAR-T therapy in China—how should this be done?

Published:2021-10-25 Issue:1 Volume:19 Page:122-124
ISSN:1672-7681
Container-title:Cellular & Molecular Immunology
language:en
Short-container-title:Cell Mol Immunol

Author:

Li Xiaolei^ORCID,Dai Hanren^ORCID,Li Xian,Li Ping,Qian Wenbin^ORCID,Liang Aibin,Han Weidong^ORCID

Funder

National Natural Science Foundation of China

China Postdoctoral Science Foundation

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Link

https://www.nature.com/articles/s41423-021-00789-3.pdf

Reference12 articles.

1. Dai H, Wang Y, Lu X, Han W. Chimeric antigen receptors modified T-cells for cancer therapy. J Natl Cancer Inst. 2016;108:djv439.

2. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725–33.

3. Varade J, Magadan S, Gonzalez-Fernandez A. Human immunology and immunotherapy: main achievements and challenges. Cell Mol Immunol. 2021;18:805–28.

4. Mullard A. FDA approves first BCMA-targeted CAR-T cell therapy. Nat Rev Drug Discov. 2021;20:332.

5. Mullard A. FDA approves fourth CAR-T cell therapy. Nat Rev Drug Discov. 2021;20:166.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP